Is pheochromocytoma associated with hypoglycemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pheochromocytoma and Hypoglycemia

Pheochromocytoma is primarily associated with hyperglycemia and glucose intolerance, not hypoglycemia, though hypoglycemia can occur as a rare complication in specific clinical contexts.

Primary Metabolic Association: Hyperglycemia

Pheochromocytoma typically causes hyperglycemia through catecholamine excess. The tumor produces excessive catecholamines that antagonize insulin action, leading to impaired glucose tolerance and diabetes 1. This occurs in individuals with preexisting defects in insulin secretion, and the hyperglycemia typically resolves when the hormone excess is resolved 1.

  • Excess catecholamines (epinephrine, norepinephrine) create a glucose-intolerant state that can manifest as resistant diabetes, diabetic ketoacidosis (DKA), or hyperglycemic hyperosmolar states (HHS) 2
  • These glycemic abnormalities often resolve completely following surgical resection of the tumor 2

When Hypoglycemia Can Occur: Three Specific Scenarios

1. Postoperative Hypoglycemia (Most Common)

Hypoglycemia most commonly occurs in the immediate postoperative period after pheochromocytoma resection due to abrupt withdrawal of catecholamines 3, 4, 5, 2, 6.

  • The mechanism involves sudden removal of catecholamine-mediated suppression of insulin, leading to unopposed insulin secretion from pancreatic beta cells 4, 5, 6
  • Preoperative alpha blockade with phenoxybenzamine without concomitant beta blockade may predispose to postoperative hypoglycemia 4
  • Beta blockade with propranolol impairs both hepatic glucose production and glucagon secretion, further increasing hypoglycemia risk 6
  • Close perioperative blood glucose monitoring is essential in all patients undergoing adrenalectomy for pheochromocytoma 5, 6
  • Hypoglycemia can be difficult to recognize postoperatively due to altered consciousness from anesthesia, analgesics, and adrenergic blocking medications 5

2. Rare Preoperative "Reactive Hypoglycemia"

In rare cases, postprandial hypoglycemia can occur preoperatively when insulin secretion stimulated by beta-2 adrenoreceptors overwhelms glucagon production 3, 2.

  • This occurs predominantly with epinephrine-producing tumors due to dramatic downstream effects of beta adrenoceptor agonization 2
  • The phenomenon represents an unusual presentation that can challenge even experienced clinicians 2

3. Associated Genetic Syndromes

Severe hypoglycemia may occur in inherited diseases linked to pheochromocytoma, particularly von Hippel-Lindau (VHL) disease 2.

Clinical Implications and Monitoring

Clinicians must maintain high vigilance for both hyperglycemic and hypoglycemic complications throughout the perioperative period 2.

  • Preoperatively: Screen for glucose intolerance and diabetes, which are the expected metabolic derangements 1
  • Perioperatively: Monitor blood glucose closely during surgery 6
  • Postoperatively: Intensive glucose monitoring is mandatory for early detection and treatment of hypoglycemia 5, 6
  • Consider the patient's preoperative medication regimen, particularly the use of alpha blockade alone versus combined alpha-beta blockade 4

Key Takeaway

While pheochromocytoma is fundamentally a hyperglycemic disorder due to catecholamine excess antagonizing insulin action 1, hypoglycemia represents an important but uncommon complication that occurs primarily after tumor resection 3, 4, 5, 2, 6. The association with hypoglycemia is paradoxical and context-dependent, requiring awareness and appropriate perioperative glucose monitoring protocols.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.